Quick Answer
Medicenna Therapeutics Corp. reported R&D Expense of $9.30 million for fiscal year 2023.
Medicenna Therapeutics Corp. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $9.30M | -36.8% |
| 2022 | $14.72M | +35.4% |
| 2021 | $10.87M | +85.2% |
| 2020 | $5.87M | — |
- Medicenna Therapeutics Corp. showed a decrease of -36.8% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2023 period, Medicenna Therapeutics Corp.’s r&d expense has grown by 58.5% (from $5.87 million to $9.30 million).
- The most recent figure is from Medicenna Therapeutics Corp.’s fiscal year 2022 report (Form 20-F), filed with the SEC on June 27, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: